Press release
Persistent corneal epithelial defects (PCEDs) Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | Eyevance, Amber Ophthalmics, Kala Pharmaceuticals, Noveome Biotherapeutics, Oyster Point Pharma
Persistent corneal epithelial defects Pipeline Analysis 2025 by DelveInsight
Persistent corneal epithelial defects (PCEDs) Overview:
The cornea, the eye's clear and outermost layer, plays a crucial role in vision by evenly bending most incoming light toward the lens. Its multi-layered epithelial surface serves as a protective shield against infections through tight junctions between adjacent cells and maintains a smooth optical surface through continuous regeneration of basal cells. Persistent Corneal Epithelial Defects (PCEDs), also known as PEDs or PCEDs, occur when the corneal surface fails to rapidly heal and close within 10-14 days following an injury, despite appropriate supportive care. Damage to the epithelial and stromal layers can leave the eye vulnerable to infections, stromal ulcers, perforations, scarring, and significant vision impairment.
Download our report @ https://www.delveinsight.com/report-store/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
"Persistent corneal epithelial defects (PCEDs) Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Persistent corneal epithelial defects (PCEDs) Therapeutics Market.
Key Takeaways from the Persistent corneal epithelial defects (PCEDs) Pipeline Report
DelveInsight's Persistent corneal epithelial defects (PCEDs) pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for Persistent corneal epithelial defects (PCEDs) treatment.
In April 2023, the FDA granted Fast Track designation to Kala Pharmaceuticals' KPI-012, a human mesenchymal stem cell secretome (MSC-S) therapy. This designation aims to expedite the development and review of treatments for serious conditions with unmet medical needs. KPI-012 is being evaluated in a Phase 2b trial (CHASE study) for its potential to treat PCEDs across various causes, including neurotrophic keratitis and chemical trauma. Early trial results showed promising safety data, and Kala anticipates reporting top-line safety and efficacy data in the first quarter of 2024.
Key Persistent corneal epithelial defects (PCEDs) companies such as Eyevance, Amber Ophthalmics, Kala Pharmaceuticals, Noveome Biotherapeutics, Oyster Point Pharma, and others are evaluating new drugs for Persistent corneal epithelial defects (PCEDs) to improve the treatment landscape.
Promising Persistent corneal epithelial defects (PCEDs) therapies include KPI-012, Nexagon, and others.
Persistent corneal epithelial defects (PCEDs) Pipeline Analysis
The Persistent corneal epithelial defects (PCEDs) pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Persistent corneal epithelial defects (PCEDs) Market.
Categorizes Persistent corneal epithelial defects (PCEDs) therapeutic companies by development stage: early, mid, and late-stage.
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
Reviews emerging Persistent corneal epithelial defects (PCEDs) drugs under development based on:
Stage of development
Persistent corneal epithelial defects (PCEDs) Route of administration
Target receptor
Monotherapy vs. combination therapy
Persistent corneal epithelial defects (PCEDs) Mechanism of action
Molecular type
Offers detailed analysis of:
Company-to-company and company-academia collaborations
Persistent corneal epithelial defects (PCEDs) Licensing agreements
Funding and investment activities supporting future Persistent corneal epithelial defects (PCEDs) market advancement.
Request for a sample report @ https://www.delveinsight.com/sample-request/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Persistent corneal epithelial defects (PCEDs) Emerging Drugs
KPI-012: Kala Pharmaceuticals
Kala Pharmaceuticals is developing KPI-012, a treatment for persistent corneal epithelial defect (PCED), a rare corneal healing disorder. They are also exploring its use for other rare front-of-eye conditions like partial limbal stem cell deficiency and moderate-to-severe Sjögren's. KPI-012 is currently in a Phase II trial, expected to complete by February 2024. Kala acquired Combangio, Inc. in November 2021 to advance KPI-012, a therapy based on a proprietary mesenchymal stem cell secretome (MSC-S) platform.
Nexagon: Eyevance/Amber Ophthalmics
NEXAGON is a first-in-class unmodified antisense oligodeoxynucleotide that targets connexin43 (Cx43), a membrane protein overexpressed after injury or in chronic disease. Elevated Cx43 leads to pathological hemichannel opening, releasing ATP and activating inflammatory pathways that cause vessel leakage and limbal ischemia. By inhibiting Cx43, NEXAGON reduces inflammation, restores limbal microvasculature, and supports corneal epithelial regeneration.
Persistent corneal epithelial defects (PCEDs) Companies
Around five or more key companies are actively developing therapies for Persistent Corneal Epithelial Defects (PCEDs), with several having drug candidates currently in advanced development, specifically in Phase II trials.
DelveInsight's report covers around 5+ products under different phases of Persistent corneal epithelial defects (PCEDs) clinical trials like
Persistent corneal epithelial defects (PCEDs) Late stage Therapies (Phase III)
Persistent corneal epithelial defects (PCEDs) Mid-stage Therapies (Phase II)
Persistent corneal epithelial defects (PCEDs) Early-stage Therapies (Phase I)
Persistent corneal epithelial defects (PCEDs) Pre-clinical and Persistent corneal epithelial defects (PCEDs) Discovery stage Therapies
Persistent corneal epithelial defects (PCEDs) Discontinued & Inactive Therapies
Persistent corneal epithelial defects (PCEDs) pipeline report provides the Persistent corneal epithelial defects (PCEDs) therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Persistent corneal epithelial defects (PCEDs) Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Persistent corneal epithelial defects (PCEDs) Therapies and Key Persistent corneal epithelial defects (PCEDs) Companies: Persistent corneal epithelial defects (PCEDs) Clinical Trials and recent advancements https://www.delveinsight.com/report-store/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Persistent corneal epithelial defects (PCEDs) Pipeline Therapeutic Assessment
• Persistent corneal epithelial defects (PCEDs) Assessment by Product Type
• Persistent corneal epithelial defects (PCEDs) By Stage
• Persistent corneal epithelial defects (PCEDs) Assessment by Route of Administration
• Persistent corneal epithelial defects (PCEDs) Assessment by Molecule Type
Download Persistent corneal epithelial defects (PCEDs) Sample report to know in detail about the Persistent corneal epithelial defects (PCEDs) treatment market @ Persistent corneal epithelial defects (PCEDs) Therapeutic Assessment https://www.delveinsight.com/sample-request/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Persistent corneal epithelial defects (PCEDs) Current Treatment Patterns
4. Persistent corneal epithelial defects (PCEDs) - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Persistent corneal epithelial defects (PCEDs) Late-Stage Products (Phase-III)
7. Persistent corneal epithelial defects (PCEDs) Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Persistent corneal epithelial defects (PCEDs) Discontinued Products
13. Persistent corneal epithelial defects (PCEDs) Product Profiles
14. Persistent corneal epithelial defects (PCEDs) Key Companies
15. Persistent corneal epithelial defects (PCEDs) Key Products
16. Dormant and Discontinued Products
17. Persistent corneal epithelial defects (PCEDs) Unmet Needs
18. Persistent corneal epithelial defects (PCEDs) Future Perspectives
19. Persistent corneal epithelial defects (PCEDs) Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Persistent corneal epithelial defects (PCEDs) Pipeline Reports Offerings: https://www.delveinsight.com/report-store/persistent-corneal-epithelial-defects-pceds-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Persistent corneal epithelial defects (PCEDs) Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | Eyevance, Amber Ophthalmics, Kala Pharmaceuticals, Noveome Biotherapeutics, Oyster Point Pharma here
News-ID: 3989480 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Persistent
Evolving Market Trends In The Advanced Persistent Threat Protection Industry: In …
The Advanced Persistent Threat Protection Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Advanced Persistent Threat Protection Market Size During the Forecast Period?
The market size for advanced persistent threat protection has seen a substantial increase in the recent past. It is…
Advanced Persistent Threat Protection Market Size and Forecast
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The global Advanced Persistent Threat Protection Market is expected to record a CAGR of XX.X% from 2024 to 2031 In 2024, the market size is projected to reach a valuation of USD XX.X Billion. By 2031 the valuation is anticipated to reach USD XX.X Billion.
The Advanced Persistent Threat (APT) Protection market is experiencing significant growth due to the increasing frequency and sophistication of cyberattacks. APTs are long-term,…
Decentralized Identity Systems Market Dynamics and Demand A Deep Dive into Trend …
The Decentralized Identity Systems Market is an emerging and transformative sector within the blockchain and digital identity industries, offering a secure and user-centric approach to managing identity information. Decentralized identity systems empower individuals to have more control over their personal data and digital identities, reducing reliance on centralized entities for identity verification. These systems utilize blockchain technology and cryptography to provide secure, privacy-enhancing, and interoperable solutions for identity management. As…
Global Advanced Persistent Threat Protection Market
The data examined by GME predicted that by 2026, the Global Advanced Persistent Threat Protection Market would grow with a CAGR value of 19.5 percent. External threats are constantly on the lookout for opportunities to hack security networks and obtain access to sensitive data. Hence, with the rising cases of cyber security thefts or crime will help propel the market from 2021 to 2026. Moreover the market is projected to…
Pyrometer Market Expansion to be Persistent During 2028
Pyrometer Market – Notable Developments
In April 2019, AMETEK Land revealed its enhanced SPOT infrared pyrometer software packages, SPOTPro and SPOTViewer. The newly launched pyrometer packages are aimed at giving users a better understand of the performance of various processes and aid them in realizing industry 4.0 connectivity.
In December 2018, Extech announced launch of a ruggedized, dual-laser infrared (IR) thermometer named IR320, which is designed to perform rough and tough jobs…
DevSecOps Market Expansion to be Persistent during 2023
Overview:
In the recent times, a new trend is gaining popularity in the software development life cycle called DevSecOps. This technology bridges the gap between development, operations, and security teams to speed up the software development process through collaboration and communication among the teams. The goal of DevOps is to give more ownership to the development team for developing and monitoring applications. Security plays a key role by providing high-end security…
